

**Product Name** : BX430

**Synonyms** : —

**Cat No.** : M22122

**CAS Number** : 688309-70-8

**Molecular Formula** : C<sub>15</sub>H<sub>15</sub>BrN<sub>3</sub>O

**Formula Weight** : 413.11

**Chemical Name** : —

**Description** : BX430 is used for chronic pain and cardiovascular disease and it is a potent and selective noncompetitive allosteric human P2X<sub>4</sub> receptor channels antagonist with an IC<sub>50</sub> of 0.54 μM. BX430 has species specificity. BX430, with submicromolar potency (IC<sub>50</sub> = 0.54 M). BX430 is highly selective, having virtually no functional impact on all other P2X subtypes, namely, P2X<sub>1</sub>-P2X<sub>3</sub>, P2X<sub>5</sub>, and P2X<sub>7</sub>, at 10-100 times its IC<sub>50</sub>. Unexpected species differences were noticed, as BX430 is a potent antagonist of zebrafish P2X<sub>4</sub> but has no effect on rat and mouse P2X<sub>4</sub> orthologs. The concentration-response curve for ATP on human P2X<sub>4</sub> in the presence of BX430 shows an insurmountable blockade, indicating a noncompetitive allosteric mechanism of action. Using a fluorescent dye uptake assay, we observed that BX430 also effectively suppresses ATP-evoked and ivermectin-potentiated membrane permeabilization induced by P2X<sub>4</sub> pore dilation. Finally, in single-cell calcium imaging, we validated its selective inhibitory effects on native P2X<sub>4</sub> channels at the surface of human THP-1 cells that were differentiated into macrophages. In summary, this ligand provides a novel molecular probe to assess the specific role of P2X<sub>4</sub> in inflammatory and neuropathic conditions, where ATP signaling has been shown to be dysfunctional.

**Pathway** : Neuroscience

**Target** : P2 Receptor

**Receptor** : human P2X<sub>4</sub> receptor channels

**Solubility** : —

**SMILES** : CC(C)c1cc(Br)c(NC(=O)Nc2ccnc2)c(Br)c1

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Ase AR, et al. Identification and characterization of a selective allosteric antagonist of human P2X<sub>4</sub> receptor channels. Mol Pharmacol. 2015 Apr;87(4):606-16.